These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 15203030)

  • 1. Liquid chromatography method for the quantitation of the breast cancer resistance protein ABCG2 inhibitor fumitremorgin C and its chemical analogues in mouse plasma and tissues.
    Garimella TS; Ross DD; Bauer KS
    J Chromatogr B Analyt Technol Biomed Life Sci; 2004 Aug; 807(2):203-8. PubMed ID: 15203030
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma pharmacokinetics and tissue distribution of the breast cancer resistance protein (BCRP/ABCG2) inhibitor fumitremorgin C in SCID mice bearing T8 tumors.
    Garimella TS; Ross DD; Eiseman JL; Mondick JT; Joseph E; Nakanishi T; Bates SE; Bauer KS
    Cancer Chemother Pharmacol; 2005 Feb; 55(2):101-9. PubMed ID: 15580504
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C.
    Allen JD; van Loevezijn A; Lakhai JM; van der Valk M; van Tellingen O; Reid G; Schellens JH; Koomen GJ; Schinkel AH
    Mol Cancer Ther; 2002 Apr; 1(6):417-25. PubMed ID: 12477054
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential inhibition of murine Bcrp1/Abcg2 and human BCRP/ABCG2 by the mycotoxin fumitremorgin C.
    González-Lobato L; Real R; Prieto JG; Alvarez AI; Merino G
    Eur J Pharmacol; 2010 Oct; 644(1-3):41-8. PubMed ID: 20655304
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sensitive method for plasma and tumor Ko143 quantification using reversed-phase high-performance liquid chromatography and fluorescence detection.
    Zander SA; Beijnen JH; van Tellingen O
    J Chromatogr B Analyt Technol Biomed Life Sci; 2013 Jan; 913-914():129-36. PubMed ID: 23291288
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overexpression of the ATP-binding cassette half-transporter, ABCG2 (Mxr/BCrp/ABCP1), in flavopiridol-resistant human breast cancer cells.
    Robey RW; Medina-Pérez WY; Nishiyama K; Lahusen T; Miyake K; Litman T; Senderowicz AM; Ross DD; Bates SE
    Clin Cancer Res; 2001 Jan; 7(1):145-52. PubMed ID: 11205902
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of breast cancer resistance protein in acute lymphoblastic leukemia.
    Plasschaert SL; van der Kolk DM; de Bont ES; Kamps WA; Morisaki K; Bates SE; Scheffer GL; Scheper RJ; Vellenga E; de Vries EG
    Clin Cancer Res; 2003 Nov; 9(14):5171-7. PubMed ID: 14613996
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gefitinib ("Iressa", ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein/ABCG2-mediated drug resistance.
    Nakamura Y; Oka M; Soda H; Shiozawa K; Yoshikawa M; Itoh A; Ikegami Y; Tsurutani J; Nakatomi K; Kitazaki T; Doi S; Yoshida H; Kohno S
    Cancer Res; 2005 Feb; 65(4):1541-6. PubMed ID: 15735043
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fumitremorgin C reverses multidrug resistance in cells transfected with the breast cancer resistance protein.
    Rabindran SK; Ross DD; Doyle LA; Yang W; Greenberger LM
    Cancer Res; 2000 Jan; 60(1):47-50. PubMed ID: 10646850
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Membrane transport of dietary phenethyl isothiocyanate by ABCG2 (breast cancer resistance protein).
    Ji Y; Morris ME
    Mol Pharm; 2005; 2(5):414-9. PubMed ID: 16196494
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Determination of mitiglinide in rat plasma by high-performance liquid chromatography with UV detection.
    Lushan Y; Su Z
    J Chromatogr B Analyt Technol Biomed Life Sci; 2006 Apr; 834(1-2):204-7. PubMed ID: 16520101
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Investigation of quinazolines as inhibitors of breast cancer resistance protein (ABCG2).
    Juvale K; Gallus J; Wiese M
    Bioorg Med Chem; 2013 Dec; 21(24):7858-73. PubMed ID: 24184213
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Small intestinal efflux mediated by MRP2 and BCRP shifts sulfasalazine intestinal permeability from high to low, enabling its colonic targeting.
    Dahan A; Amidon GL
    Am J Physiol Gastrointest Liver Physiol; 2009 Aug; 297(2):G371-7. PubMed ID: 19541926
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HM30181 Derivatives as Novel Potent and Selective Inhibitors of the Breast Cancer Resistance Protein (BCRP/ABCG2).
    Köhler SC; Wiese M
    J Med Chem; 2015 May; 58(9):3910-21. PubMed ID: 25855895
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of dihydropyridines and pyridines on multidrug resistance mediated by breast cancer resistance protein: in vitro and in vivo studies.
    Zhou XF; Yang X; Wang Q; Coburn RA; Morris ME
    Drug Metab Dispos; 2005 Aug; 33(8):1220-8. PubMed ID: 15908473
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reversal of breast cancer resistance protein (BCRP/ABCG2)-mediated drug resistance by novobiocin, a coumermycin antibiotic.
    Shiozawa K; Oka M; Soda H; Yoshikawa M; Ikegami Y; Tsurutani J; Nakatomi K; Nakamura Y; Doi S; Kitazaki T; Mizuta Y; Murase K; Yoshida H; Ross DD; Kohno S
    Int J Cancer; 2004 Jan; 108(1):146-51. PubMed ID: 14618629
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Piperazinobenzopyranones and phenalkylaminobenzopyranones: potent inhibitors of breast cancer resistance protein (ABCG2).
    Boumendjel A; Nicolle E; Moraux T; Gerby B; Blanc M; Ronot X; Boutonnat J
    J Med Chem; 2005 Nov; 48(23):7275-81. PubMed ID: 16279786
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A high-performance liquid chromatography method using ultraviolet detection for the quantitation of flavopiridol from human plasma.
    Zhai S; Sausville E; Figg WD
    Biomed Chromatogr; 2002 Sep; 16(6):379-82. PubMed ID: 12228893
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phytoestrogens/flavonoids reverse breast cancer resistance protein/ABCG2-mediated multidrug resistance.
    Imai Y; Tsukahara S; Asada S; Sugimoto Y
    Cancer Res; 2004 Jun; 64(12):4346-52. PubMed ID: 15205350
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A high-throughput cell-based assay for inhibitors of ABCG2 activity.
    Henrich CJ; Bokesch HR; Dean M; Bates SE; Robey RW; Goncharova EI; Wilson JA; McMahon JB
    J Biomol Screen; 2006 Mar; 11(2):176-83. PubMed ID: 16490770
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.